Amoeba : 13/04/22 - Availability of the 2021 Universal Registration Document

PRESS RELEASE

AMOÉBA announces the availability of the 2021 Universal Registration Document including the Annual Financial Report

Lyon (France), April 13, 2022 -8.30 am- AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in a development phase, announces that the 2021 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 12, 2022 under number D.22-0280.

The 2021 Universal Registration Document includes:

• - the Annual Financial Report comprising the consolidated financial statements, the parent company financial statements, the management report and the related statutory auditors'

  reports

• - the Board of Directors' corporate governance report.

The Universal Registration Document 2021 also presents the company's activities, particularly in the development of the biocidal and biocontrol applications and its research works. The organisation, financial situation, results and prospects of Amoéba are also described in the Document.

The document may be viewed or downloaded on the company's websitewww.amoeba-nature.com under section "Investors / financial documents/ Reference Document". Copies of the Universal Registration Document are also available at the company's headquarters: 38, avenue des frères

Montgolfier, 69680 Chassieu, France.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information onwww.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets (3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:Amoéba

Valérie FILIATRE Directeur Général Adjoint [phone]

Calyptus

Relations investisseurs & Presse Nicolas Hélin / Mathieu CALLEUX [phone] /[e-mail]